Preventing atrial fibrillation (af) with the use of statin drugs
CA 2529367 C · Owner: Nattel, Stanley · Inventors: Nattel, Stanley
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel method to prevent or attenuate atrial fibrillation (AF) promotion resulting from atrial tachycardia. In a study conducted with 39 dogs, the HMG-CoA reductase inhibitor simvastatin was found to significantly attenuate AF promotion. This finding constitutes the basis for an interesting new pharmaceutical approach for preventing the consequences of atrial tachycardia remodeling.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 18, 2004 and granted September 11, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 18, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 18, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.